Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

Figure 1

Radotinib enhances cytolytic activity of PBLs against A549 cells, but not K562 cells. (a) A CML cell line, K562, was treated with various concentrations of radotinib for 24 h to determine the direct effect of radotinib on K562 cell death. A trypan blue exclusive assay was performed to count live cells. (b) PBLs were isolated from healthy donors and incubated with 0 or 100 μM radotinib for 48 h. IL-2 was used as a positive control. To perform the cytotoxicity assay, K562 or A549 cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and then used as target cells. Radotinib-stimulated PBLs were incubated with CFSE-labeled target cells for 2 h (E : T  : 1) to measure the cytolytic activity of PBLs. After incubation, cells were stained with 7-AAD, and FACSCalibur was used to analyze CFSE and 7-AAD double-positive target cells. Data are reported as . All values were analyzed by unpaired Student’s -tests using GraphPad Prism 5. and . All data presented are representative of three independent experiments.

(a)

(b)